“Bashers are gone.” They’re not. They’r

“Bashers are gone.”

They’re not. They’re always here, waiting for the opportunity to short the stock when the opportunity presents itself. With data expected mid-July, they could attempt a small “attack” given the sharp rise in SP over the past 6 trading days.

There is risk mounting a short attack in this time frame for a number of reasons. First, if the data is good, CYDY could release initial data, such as a low death rate in the trials. Uplisting is also on the horizon, which could also drive the SP up further.

We’ll have to wait and see what the next month holds for CYDY investors. This could be the golden month or it could be another temporary set back on leronlimab’s path to HIV, cancer, and NASH (among others).

I would like to point out that if the FDA doesn’t approve leronlimab this month for COVID, and even though the SP would most likely drop after that announcement (requirement for a larger M2M trial), leronlimab is still a front runner to treat COVID. The M2M trial was filling quickly at the end and with an uptick in cases, and with a partnership with a BP, a larger trial could be filled in just over a month. There will not be a vaccine until 2021 and as of now, there isn’t another safe and effective treatment for mild, moderate and severe COVID patients. As much as a delay would be disappointing, a month or two more is all CYDY would need to get final approval.